Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

PPI-368 selected for development

April 5, 1996

Schering-Plough claims felbamate metabolite

April 5, 1996

Roche Bioscience claims antiemetic drugs

April 5, 1996

SYM-2206 for seizure prevention

April 5, 1996

Anticonvulsants claimed by Bristol-Myers Squibb

April 5, 1996

Stanford investigators identify epilepsy gene

April 5, 1996

Synthelabo reports antidepressants

April 5, 1996

5-HT1A/5-HT2C receptor ligands from Roche

April 5, 1996

New anthranilide in phase I at Glaxo Wellcome

April 5, 1996

L-745870: D4 antagonist for schizophrenia

April 5, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...